Reminder: You are viewing our sharing site. Content may differ from our live site.
Skip to main content

# Cervical dysplasia - Whole blood and components

Also known as: cervical intraepithelial neoplasia, CIN

## Essential information

Obligatory

  Must not donate if:

  1. Undergoing investigation or treatment.
  2. Diagnosed with invasive cervical carcinoma.
Discretionary
  1. If the donor had colposcopy treatment for abnormal cervical cells and has been discharged to routine screening, accept. It is not necessary to wait for a normal smear result before donating.
  2. If only having regular review of smears, accept.

## Supporting information

Additional information

  Cervical screening includes testing for high risk human papillomavirus (HR-HPV). Women who are positive for HR-HPV may be called for routine smear tests at more frequent intervals. They can donate, provided they are not undergoing other tests or awaiting colposcopy investigation.

  Women with abnormal cells on a smear test are triaged according to their risk of developing cervical carcinoma. Women at higher risk will be referred for investigation and treatment via colposcopy.

  A colposcope is an instrument used to view the neck of the womb (cervix). It is not a flexible endoscope so its use is not a reason for deferral if the donor is otherwise eligible to donate.

  Abnormalities identified at colposcopy include cervical intraepithelial neoplasia (CIN, Grades 1-3) and cervical glandular intraepithelial neoplasia (CGIN). CIN-3 is also known as cervical carcinoma in situ. By definition, patients with CIN or CGIN do not have invasive cervical carcinoma, so can be accepted once treated, fully healed and discharged. There is no need to wait for the results of their next routine smear, usually at 6 months post treatment, unless the donor has been advised that follow-up will be necessary at the colposcopy clinic.

Reason for change:
  Updated to clarify the scope of entry, when donor can return after treatment for cervical dysplasia and the significance of HR-HPV testing.
Version details:

  WB-DSG Edition 203 Release 55 (21 January 2021)

BETA

We recently updated this website. Help us improve it – give your feedback (opens in new tab)